Key Points
- Imunon General Counsel Susan Eylward sold 11,800 shares on June 29 at an average price of $1.75, totaling about $20,650. After the sale, she directly owned 2,896 shares, an 80.29% decrease in her stake.
- IMNN shares were slightly higher, opening at $1.80 and up 0.6% on Tuesday. The stock remains near its 12-month low of $1.70, far below its 12-month high of $11.19.
- Imunon recently reported a smaller-than-expected loss, posting ($0.84) EPS versus the consensus estimate of ($1.22). Analysts currently have a Hold consensus rating with a $10.00 target price.
Imunon, Inc. (NASDAQ:IMNN - Get Free Report) General Counsel Susan Eylward sold 11,800 shares of the stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $1.75, for a total value of $20,650.00. Following the transaction, the general counsel directly owned 2,896 shares of the company's stock, valued at $5,068. This trade represents a 80.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Imunon Stock Up 0.6%
Shares of Imunon stock opened at $1.80 on Tuesday. Imunon, Inc. has a 12-month low of $1.70 and a 12-month high of $11.19. The stock has a market cap of $7.56 million, a P/E ratio of -0.35 and a beta of 1.95. The business's 50 day moving average is $2.31 and its 200-day moving average is $2.99.
Imunon (NASDAQ:IMNN - Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported ($0.84) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.38. On average, sell-side analysts expect that Imunon, Inc. will post -3.46 EPS for the current year.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the company. Riverview Capital Advisers LLC lifted its holdings in shares of Imunon by 193.3% during the third quarter. Riverview Capital Advisers LLC now owns 34,364 shares of the company's stock worth $176,000 after buying an additional 22,649 shares in the last quarter. DRW Securities LLC grew its stake in shares of Imunon by 6.9% in the fourth quarter. DRW Securities LLC now owns 58,830 shares of the company's stock valued at $224,000 after acquiring an additional 3,803 shares in the last quarter. Finally, Armistice Capital LLC bought a new position in Imunon during the fourth quarter worth about $1,017,000. Institutional investors own 4.47% of the company's stock.
Analyst Ratings Changes
A number of brokerages have recently commented on IMNN. Maxim Group set a $10.00 price objective on shares of Imunon and gave the company a "buy" rating in a research report on Friday, April 17th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Imunon in a research note on Tuesday, April 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $10.00.
Get Our Latest Report on Imunon
About Imunon
(
Get Free Report)
Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
